Study of PCSK9's effect on blood platelets
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at how a protein called PCSK9 affects blood platelets in healthy people and in those with heart disease risk factors. It aims to help researchers understand if blocking PCSK9 might reduce the risk of blood clots or heart attacks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You are either generally healthy OR have at least 3 heart-disease risk factors (like high cholesterol, high blood pressure, being overweight, smoking, prediabetes/diabetes, or family history of heart disease).
- You are not currently taking high-dose statins or PCSK9 medications (like Repatha or Praluent).
- You have not had a heart attack, stroke, or needed a procedure to open blocked arteries.
- You have not taken blood-thinning medications (like aspirin, Plavix, or Eliquis) in the last 14 days.
- You are not pregnant, and do not have serious kidney, liver, or other chronic conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
This trial tests whether a single injection of a PCSK9 inhibitor (a cholesterol-lowering medicine) can improve heart health after a stent procedure. It is for people who have a certain amount of fat buildup in their treated artery.
This trial tests whether a powerful cholesterol-lowering drug (PCSK9 inhibitor) helps stabilize plaque in heart arteries after a recent heart attack or unstable angina treated with a stent. It may lower the risk of future heart problems.
Hear when a new Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.